Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Merck
Dow
Baxter
McKinsey

Last Updated: August 11, 2022

CLINICAL TRIALS PROFILE FOR IXABEPILONE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for ixabepilone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004927 ↗ BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Completed Memorial Sloan Kettering Cancer Center Phase 1 1999-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy.
NCT00004927 ↗ BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Completed National Cancer Institute (NCI) Phase 1 1999-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy.
NCT00004927 ↗ BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Completed Bristol-Myers Squibb Phase 1 1999-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors that have not responded to previous therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ixabepilone

Condition Name

Condition Name for ixabepilone
Intervention Trials
Breast Cancer 23
Metastatic Breast Cancer 18
Unspecified Adult Solid Tumor, Protocol Specific 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ixabepilone
Intervention Trials
Breast Neoplasms 47
Neoplasms 15
Carcinoma 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ixabepilone

Trials by Country

Trials by Country for ixabepilone
Location Trials
United States 608
Italy 25
Japan 18
United Kingdom 17
Australia 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ixabepilone
Location Trials
California 30
New York 30
Maryland 29
Florida 28
Texas 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ixabepilone

Clinical Trial Phase

Clinical Trial Phase for ixabepilone
Clinical Trial Phase Trials
Phase 3 7
Phase 2 65
Phase 1/Phase 2 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ixabepilone
Clinical Trial Phase Trials
Completed 82
Terminated 19
Active, not recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ixabepilone

Sponsor Name

Sponsor Name for ixabepilone
Sponsor Trials
National Cancer Institute (NCI) 53
Bristol-Myers Squibb 28
R-Pharm 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ixabepilone
Sponsor Trials
Industry 78
Other 71
NIH 54
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
McKesson
Mallinckrodt
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.